title: Effects of combined therapy with glipizide and Aralia root bark extract on glycemic control and lipid profiles in patients with type 2 diabetes mellitus.
abstract: BACKGROUND
  The root bark of Aralia is a rich source of bioactive components that may improve glycemic control and lipid status. In this study, 148 patients with type 2 diabetes mellitus (T2DM) were assigned randomly to receive either glipizide alone or glipizide plus Aralia root bark extract (ARBE) for 8 weeks to test the effects of ARBE plus glipizide therapy on glycemic control and lipid profiles in these patients.
  
  
  RESULTS
  Levels of HbA1c, fasting plasma glucose (FPG) and 2 h postprandial plasma glucose (2-h PPG) in both groups significantly decreased from baseline. Glycated hemoglobin (HbA1c) decreased marginally significantly in participants taking glipizide plus ARBE compared with the glipizide group (P = 0.06). Participants in the combination group had significant decreases in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), and the between-group difference achieved statistical significance for LDL-C (P = 0.04). Reduction in HbA1c in the combination group was significantly associated with changes in TC (r = 0.32; P = 0.006) and LDL-C (r = 0.34; P = 0.005), and the change in FPG was inversely correlated with LDL-C reduction (r = 0.34; P = 0.004).
  
  
  CONCLUSIONS
  In patients with T2DM, combination therapy with glipizide and ARBE resulted in moderately lowering HbA1c and LDL-C levels compared with glipizide alone.
authors.affiliation: The First Affiliated Hospital, Xi'an Jiaotong University College of Medicine, 277 Yanta West Road, Xi'an, Shaanxi, 710061, China.
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Liu
authors.forename: Xing-Min
authors.initials: XM
authors.lastname: Li
authors.forename: Cheng-Cheng
authors.initials: CC
authors.lastname: Han
authors.forename: Xiang-Feng
authors.initials: XF
authors.lastname: Fang
authors.forename: Le
authors.initials: L
authors.lastname: Ma
mesh_terms: D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use*; D027983:Aralia / Q000737:chemistry*; D002681:China; D003131:Combined Modality Therapy / Q000009:adverse effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000178:diet therapy* / Q000188:drug therapy; D019587:Dietary Supplements / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D005913:Glipizide / Q000627:therapeutic use; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D006949:Hyperlipidemias / Q000150:complications / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D057194:Intention to Treat Analysis; D059012:Lost to Follow-Up; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts; D024301:Plant Bark / Q000737:chemistry*; D010936:Plant Extracts / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000975:Antioxidants; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D010936:Plant Extracts; D005913:Glipizide
keywords: Aralia; antioxidants; glycemic control; lipid status; type 2 diabetes mellitus